Potential combined drug therapy for lung cancer
Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of…
Browsing: NSCLC
Potential treatment for an aggressive form of lung cancer
Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI), USA, have discovered…
Drugs create balancing act for patients with non-small cell lung cancer
The results of a large, retrospective study of patients who received a form of immunotherapy…
New drug for difficult-to-drug cancer mutation could be key treatment for a range of cancers
A new drug designed to counter the effects of an important, but very hard to…
Precision trial highlights need for new approach to treating genomically complex cancers
A pioneering lung cancer study, led by the University of Birmingham’s Cancer Research UK Clinical…
Blood test can predict clinical response to immunotherapy in metastatic NSCLC
Non-small cell lung cancer (NSCLC) patients with higher measures of tumour mutations that show up…
Update on Genetic Testing in Cancer and Targeted Therapy
Cancer, a leading cause of mortality, is associated with aberrant genes. Many of the most…
Dynamic transition of the blood-brain barrier in the development of NSCLC brain metastases
Effective drug delivery through the blood-tumour barrier (BTB) is one of the greatest therapeutic obstacles…
Protected: Immunotherapy combination now PBS listed for first-line treatment of metastatic non-squamous non-small cell lung cancer (1,2)
This content is password protected. To view it please enter your password below: Password:
Taking baby aspirin improves overall survival for patients with head/neck and lung cancer
What if a drug that sits in nearly everyone’s medicine cabinet could help extend the…